FDA approves new Kisunla dosing regimen to lower ARIA-E risk
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
A breast cancer diagnosis is particularly problematic — yet possible — for women caregivers, columnist Ray Burow writes.| Alzheimer's News Today
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto...| Alzheimer's News Today
The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ADVANCE-2 didn't.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
